logo
Customer's disgusting surprise in salad leaves her scarred for life

Customer's disgusting surprise in salad leaves her scarred for life

Daily Mail​09-05-2025
A woman in New York City was horrified after she bought takeout only to find a rodent mixed in with her salad leaves.
Hannah Rasbach, 27, ordered a salad from a restaurant in Midtown Manhattan but was disgusted by the unwanted addition.
'When I tried to cut it, it didn't feel right, it felt like a fatty piece of meat or something...' she told ABC 7 grimacing.
'I took a better look and I saw the tail and eyes.'
Rasbach was halfway through her meal when she found the rodent and immediately took the container of food back to the restaurant.
Footage showed her inside Ongi on West 37th Street on Monday afternoon talking with an employee before handing over the food.
'[The employee] asked if I thought it had come from the spring mix...obviously, I'm not sure where it came from,' Rasbach continued.
She rushed to the doctor and was put on antibiotics as a precaution, concerned that the rodent may have urinated or defecated on the food.
'We had no idea how this animal died, it could have been rat poison, it could have been disease, any number of things,' she said.
Rasbach told the outlet she can't imagine eating out again ever again.
The owner, Ray Park, handed over the footage to the outlet insisting that the rodent didn't come from his restaurant.
'I was thinking, how can it be happening here, because we have a high standard to run every single day here,' Park told ABC 7.
He added that he had no idea where the rodent came from, and didn't want to guess, as he revealed the establishment had combed over the footage countless times.
'If I use my finger, it's this big including the tail. It's not small,' Park continued.
He said that the kitchen is clean and there had never been evidence of droppings. He kept Rasbach's meal as evidence, he told the outlet.
Rasbach filed a complaint with 311 and the Health Department said it's investigating.
'I would like them to be shut down or investigated,' she said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Menopause made my hair fall out. Then I discovered a new hair-loss solution. This is the secret ALL midlife women need to know
Menopause made my hair fall out. Then I discovered a new hair-loss solution. This is the secret ALL midlife women need to know

Daily Mail​

time2 hours ago

  • Daily Mail​

Menopause made my hair fall out. Then I discovered a new hair-loss solution. This is the secret ALL midlife women need to know

For me, midlife has brought various indignities, as well as many joys. But standing over a sink to count the number of hairs that had come out in my brush one morning has to be among the more distressing aspects. For the record, it was 201. And why was I counting them? Because I'd searched 'how to tell if your hair is falling out' online – and according to Dr Google, anything over 100 strands was a cause for concern.

WeightWatchers boss says ‘exciting work to do' amid impact of weight loss jabs
WeightWatchers boss says ‘exciting work to do' amid impact of weight loss jabs

The Independent

time3 hours ago

  • The Independent

WeightWatchers boss says ‘exciting work to do' amid impact of weight loss jabs

WeightWatchers was slower to adapt to the emergence of anti-obesity jabs than rivals, its boss has admitted, as the 62-year-old brand strives to catch up with rapidly evolving attitudes towards weight loss. Tara Comonte, chief executive of the US-based business, said it had a lot of work to do after going through a 'reset'. WeightWatchers recently announced it had emerged from bankruptcy after writing off a portion of the 1.15 billion US dollar (£860 million) debt on its balance sheet. It came as the business was competing with the emergence of GLP-1s – the scientific term for weight loss jabs, which work by reducing food cravings – and a new wave of apps and advice spreading on social media. Ms Comonte told the PA news agency that it 'wasn't as quick to medical weight loss solutions' as some other firms in the US, notably so-called 'telehealth' businesses that offer healthcare remotely. WeightWatchers, which runs some 20,000 workshops each month globally, is now 'at the beginning of the journey' towards forging a new place in the industry and meeting demand from current and future members, Ms Comonte said. 'This whole industry is going through somewhat of a reset and we have exciting work to do,' she told the PA news agency. 'This is a moment where, possibly more than ever before, people are talking about weight, and weight health… where people are seeking more education than ever before, and there are more voices than ever before.' Ms Comonte said the brand was known for 'trust and science' and it was important to harness that 'as there are more and more voices in the ecosystem'. WeightWatchers recently partnered with anti-obesity drugs provider CheqUp in the UK so patients taking the medication can access its 'companion' diet and lifestyle support app. It forms part of its efforts to muscle into the market by offering behavioural strategies and community-based support to people using or coming off the medication. 'There's no 'us and them' anymore,' Ms Comonte told PA, hitting back at weight loss jabs often being pitted as rivals to its model. Dr Kim Boyde, WeightWatchers' newly appointed chief medical officer, said not all its members will want or need weight loss medication – but stressed that it was 'imperative' the programme offers it to those that might benefit. Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs. Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects.

Roche to investigate whether new drug can delay or prevent Alzheimer's disease
Roche to investigate whether new drug can delay or prevent Alzheimer's disease

Reuters

time4 hours ago

  • Reuters

Roche to investigate whether new drug can delay or prevent Alzheimer's disease

July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store